Formulation study of oxybutynin patches.
The present feasibility study was designed to obtain a monolayer patch containing oxybutynin (OXY) avoiding chemical permeation enhancers. The highest flux was obtained with a polydimethylsiloxane matrix patch. Because OXY crystals were detected in the matrix within a week, two amino methylmethacrylate copolymers (Eudragit E or Eudragit RS) were used as OXY crystallization inhibitors. A preliminary in vivo study indicated that flux from the stabilized patches had to be increased about 30-40%. This goal was reached by occlusion with a polyethylene layer.
Minghetti
Paola
P
Istituto di Chimica Farmaceutica e Tossicologica Pietro Pratesi, University of Milan, Milano, Italy. paola.minghetti@unimi.it
Cilurzo
Francesco
F
Pagani
Stefania
S
Casiraghi
Antonella
A
Assandri
Riccardo
R
Montanari
Luisa
L
D002152:Calorimetry, Differential Scanning; D004339:Drug Compounding; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D066298:In Vitro Techniques; D008333:Mandelic Acids / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D018727:Muscarinic Antagonists / Q000032:analysis / Q000493:pharmacokinetics* / Q000494:pharmacology; D010539:Permeability / Q000187:drug effects; D012867:Skin / Q000187:drug effects; D017550:Spectroscopy, Fourier Transform Infrared
D008333:Mandelic Acids; D018727:Muscarinic Antagonists; C005419:oxybutynin